Do You Have These Biotech Stocks In Your Portfolio?

(RTTNews) - Drug companies spend billions on R&D, which is the lifeline of the pharma industry. According to a report published by the Tufts Center for the Study of Drug Development, it costs about $2.6 billion to develop a new drug and bring it to market.

The success rate of phase I clinical programs is the highest, say 63%, while it is the lowest for phase II trials - i.e. 30%. The phase III trials, which are the longest and most expensive trials to conduct, are said to have a success rate of 58%, according to a new report from the Biotechnology Innovation Organization on "Clinical Development Success Rates" over the past decade (2006-2015).

The clinical trial results can make or break a drug company. AERI and NVAX are two recent examples of how this binary event can impact the stock price.

Aerie Pharmaceuticals Inc. (AERI) reported positive phase III results of its second glaucoma drug candidate Roclatan on September 15, 2016, which sent its stock price up as much as 64% that day.

Novavax Inc. (NVAX) plunged more than 83% on September 16, 2016, following the failure of its phase III trial of respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate.

Listed here are some of the drug companies, which are expected to report clinical trial results this month.